机器学习MRI影像组学预测胰腺导管腺癌肿瘤浸润淋巴细胞
本研究回顾性纳入156例胰腺导管腺癌患者,基于术前MRI影像组学特征构建XGBoost分类器预测肿瘤浸润淋巴细胞(TILs)评分高低。模型在训练集AUC为0.86(95%CI 0.79-0.93),验证集AUC为0.79(95%CI 0.64-0.93),决策曲线分析显示临床有用性,可能辅助免疫治疗决策。
要点
- 基于MRI影像组学的XGBoost模型可术前预测PDAC的TILs评分高低。
- 验证集AUC为0.79,敏感度84.21%,特异度66.67%。
- 该模型可能辅助PDAC免疫治疗临床决策。
局限性
- 回顾性研究设计。
- 验证集样本量较小(40例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To develop and validate a machine learning classifier based on magnetic resonance imaging (MRI), for the preoperative prediction of tumor-infiltrating lymphocytes (TILs) in patients with pancreatic ductal adenocarcinoma (PDAC).
MATERIALS AND METHODS: In this retrospective study, 156 patients with PDAC underwent MR scan and surgical resection. The expression of CD4, CD8 and CD20 was detected and quantified using immunohistochemistry, and TILs score was achieved by Cox regression model. All patients were divided into TILs score-low and TILs score-high groups. The least absolute shrinkage and selection operator method and the extreme gradient boosting (XGBoost) were used to select the features and to construct a prediction model. The performance of the models was assessed using the training cohort (116 patients) and the validation cohort (40 patients), and decision curve analysis (DCA) was applied for clinical use.
RESULTS: The XGBoost prediction model showed good discrimination in the training (AUC 0.86; 95% CI 0.79-0.93) and validation sets (AUC 0.79; 95% CI 0.64-0.93). The sensitivity, specificity, and accuracy for the training set were 86.67%, 75.00%, and 0.81, respectively, whereas those for the validation set were 84.21%, 66.67%, and 0.75, respectively. Decision curve analysis indicated the clinical usefulness of the XGBoost classifier.
CONCLUSION: The model constructed by XGBoost could predict PDAC TILs and may aid clinical decision making for immune therapy.
引用
- Bian Y, Liu YF, Jiang H, et al. Machine learning for MRI radiomics: a study predicting tumor-infiltrating lymphocytes in patients with pancreatic ductal adenocarcinoma. Abdom Radiol (NY). 2021. PMID: 34189612. doi:10.1007/s00261-021-03159-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。